Veille documentaire MTPH

Médecine du travail du personnel hospitalier

Management of varicella contacts in pregnancy: VZIG or vaccination?

Auteur     Judith A Troughton
Auteur     Grainne Crealey
Auteur     Vivienne Crawford
Auteur     Peter V Coyle
Résumé     BACKGROUND: Varicella infection during pregnancy poses a serious risk for both foetus and mother. It has been suggested that it would be more cost-effective to screen antenatally with post-partum vaccination, which occurs in the US, than the current policy of checking immune status post varicella exposure, with VZIG administration where necessary. Additionally, it is doubtful whether the current policy provides best patient care, when a vaccine is available. OBJECTIVES: The study aims to retrospectively compare the cost of the current policy with a cost estimate for antenatal screening with post-partum vaccination in NI. STUDY DESIGN: A cost estimate of antenatal screening of primigravidas, with post-partum vaccination, was calculated for two models: (1) verbal screening, with serological testing of those with no history of varicella infection and (2) serological screening of all primigravidas. RESULTS: The cost of VZIG issued to pregnant women in 2006 was pound100,800; 43% of births were to primigravidas therefore the estimated cost of VZIG issued to multigravidas was pound58,100. The cost of verbal screening with post-partum vaccination is estimated at pound23,750 p.a., saving pound34,350 over current policy. The estimated cost of screening all primigravidas with post-partum vaccination is pound43,000, saving pound15,100. CONCLUSIONS: This retrospective study suggests that in NI either of the proposed antenatal screening strategies would be less costly than current practice. This finding supports the suggestion that varicella immunity testing should be included in the Antenatal Infectious Diseases Screening Programme, either as part of the universal vaccination programme or solely as an antenatal programme.
Publication     Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology
Volume     46
Numéro     4
Pages     345-348
Date     Dec 2009

Auteur
Judith A Troughton

Auteur
Grainne Crealey

Auteur
Vivienne Crawford

Auteur
Peter V Coyle

Résumé
BACKGROUND: Varicella infection during pregnancy poses a serious risk for both foetus and mother. It has been suggested that it would be more cost-effective to screen antenatally with post-partum vaccination, which occurs in the US, than the current policy of checking immune status post varicella exposure, with VZIG administration where necessary. Additionally, it is doubtful whether the current policy provides best patient care, when a vaccine is available. OBJECTIVES: The study aims to retrospectively compare the cost of the current policy with a cost estimate for antenatal screening with post-partum vaccination in NI. STUDY DESIGN: A cost estimate of antenatal screening of primigravidas, with post-partum vaccination, was calculated for two models: (1) verbal screening, with serological testing of those with no history of varicella infection and (2) serological screening of all primigravidas. RESULTS: The cost of VZIG issued to pregnant women in 2006 was pound100,800; 43% of births were to primigravidas therefore the estimated cost of VZIG issued to multigravidas was pound58,100. The cost of verbal screening with post-partum vaccination is estimated at pound23,750 p.a., saving pound34,350 over current policy. The estimated cost of screening all primigravidas with post-partum vaccination is pound43,000, saving pound15,100. CONCLUSIONS: This retrospective study suggests that in NI either of the proposed antenatal screening strategies would be less costly than current practice. This finding supports the suggestion that varicella immunity testing should be included in the Antenatal Infectious Diseases Screening Programme, either as part of the universal vaccination programme or solely as an antenatal programme.

Publication
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology

Volume
46

Numéro
4

Pages
345-348

Date
Dec Auteur     Judith A Troughton
Auteur     Grainne Crealey
Auteur     Vivienne Crawford
Auteur     Peter V Coyle
Résumé     BACKGROUND: Varicella infection during pregnancy poses a serious risk for both foetus and mother. It has been suggested that it would be more cost-effective to screen antenatally with post-partum vaccination, which occurs in the US, than the current policy of checking immune status post varicella exposure, with VZIG administration where necessary. Additionally, it is doubtful whether the current policy provides best patient care, when a vaccine is available. OBJECTIVES: The study aims to retrospectively compare the cost of the current policy with a cost estimate for antenatal screening with post-partum vaccination in NI. STUDY DESIGN: A cost estimate of antenatal screening of primigravidas, with post-partum vaccination, was calculated for two models: (1) verbal screening, with serological testing of those with no history of varicella infection and (2) serological screening of all primigravidas. RESULTS: The cost of VZIG issued to pregnant women in 2006 was pound100,800; 43% of births were to primigravidas therefore the estimated cost of VZIG issued to multigravidas was pound58,100. The cost of verbal screening with post-partum vaccination is estimated at pound23,750 p.a., saving pound34,350 over current policy. The estimated cost of screening all primigravidas with post-partum vaccination is pound43,000, saving pound15,100. CONCLUSIONS: This retrospective study suggests that in NI either of the proposed antenatal screening strategies would be less costly than current practice. This finding supports the suggestion that varicella immunity testing should be included in the Antenatal Infectious Diseases Screening Programme, either as part of the universal vaccination programme or solely as an antenatal programme.
Publication     Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology
Volume     46
Numéro     4
Pages     345-348
Date     Dec 20092009

Export bibliographique

Chercher cette référence sur : Google Scholar, Worldcat

doi:10.1016/j.jcv.2009.09.014

Laisser une réponse

Vous devez etre connectez Pour poster un commentaire